Seoulin Bioscience Co

Seoulin Bioscience Co FCF per Share

The Free Cash Flow per Share of Seoulin Bioscience Co (038070.KQ) as of Nov 4, 2026 is 551.40 KRW. In the previous year, Free Cash Flow per Share was -606.08 KRW — a change of -190.98% (higher).

FCF per Share

551.40KRW

YoY

-190.98%

Last updated:

Free Cash Flow per Share of Seoulin Bioscience Co is 2025 551.40 KRW. Free Cash Flow per Share of Seoulin Bioscience Co was 2024 -606.08 KRW. It decreases by -190.98% higher compared to the previous year.

The Seoulin Bioscience Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
506.04 KRW
Jan 1, 2019
914.46 KRW
Jan 1, 2020
425.74 KRW
Jan 1, 2021
939.87 KRW
Jan 1, 2022
-656.53 KRW
Jan 1, 2023
-5.66 KRW
Jan 1, 2024
-606.08 KRW
Jan 1, 2025
551.40 KRW
The Seoulin Bioscience Co FCF per Share history
YEARFCF per ShareYoY
551.40KRW-190.98%
-606.08KRW+10,608.13%
-5.66KRW-99.14%
-656.53KRW-169.85%
939.87KRW+120.76%
425.74KRW-53.44%
914.46KRW+80.71%
506.04KRW-152.77%
-958.99KRW+65.86%
-578.20KRW-1,292.18%
48.50KRW-81.09%
256.47KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seoulin Bioscience Co Stock analysis

What does Seoulin Bioscience Co do? SeouLin Bioscience Co., Ltd. generates revenue through the development and supply of reagents, including DNA chips for gene therapy, clinical diagnosis, organ transplantation, and biopsy, as well as stem cells for treating incurable diseases and Alzheimer's disease. The company markets these products under its brand MyLab and imports bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt for domestic sales. Additionally, SeouLin Bioscience operates a real estate rental business to diversify its income streams. The primary customers for MyLab reagents and stem cell therapies are healthcare providers, research institutions, and medical facilities requiring advanced diagnostic and therapeutic solutions. Domestic market distribution of imported bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt targets laboratories and hospitals seeking high-quality research tools. The real estate rental business serves commercial tenants in Seongnam, Gyeonggi-Do, where the company is headquartered. SeouLin Bioscience focuses on the lifescience sector, specifically targeting applications in gene therapy, clinical diagnostics, and regenerative medicine. Its product segments include DNA chips, stem cells, and next-generation biotechnology drugs, all under the MyLab brand. The company leverages strategic imports of bio research equipment to meet domestic demand for specialized laboratory tools. Seoulin Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seoulin Bioscience Co stock

Free Cash Flow per Share of Seoulin Bioscience Co is 551.40 KRW in 2025.

Free Cash Flow per Share of Seoulin Bioscience Co changed from -606.08 KRW to 551.40 KRW, representing a -190.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Seoulin Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Seoulin Bioscience Co

All Key Metrics — Seoulin Bioscience Co